Oxbryta FDA Recall Lawsuit Claims

Pfizer has now recalled drug Oxbryta after at least eight patients died during its clinical trials

Attention: The Schmidt National Law Group is no longer accepting these cases.

October 25, 2024 — The FDA on September 26, 2024 has notified the public via it’s consumer drug warning website of the total recall of Oxbryta. From the FDA website:

“Pfizer Inc., the manufacturer of Oxbryta, announced it is voluntarily withdrawing the medication from the market, ceasing distribution, and discontinuing all active clinical trials and expanded access programs for Oxbryta because recent data indicate the benefit of Oxbryta does not outweigh the risks for the sickle cell patient population.”

Key Points of the Oxbryta Recall:

1. Recall Reason: Pfizer’s decision was based on clinical data indicating that the overall benefits of Oxbryta no longer outweigh the risks in the approved sickle cell patient population.
2. Safety Concerns: The data suggest an imbalance in vaso-occlusive crises (VOCs) and fatal events, which require further assessment.
3. Affected Population: Oxbryta was approved for adults and children 12 years and older with sickle cell disease in 2019, with approval extended to patients 4 to 11 years old in 2021.
4. Clinical Trial Data: Two studies raised concerns:
   • A study of children with higher stroke risk (GBT440-032) reported 8 deaths in the voxelotor group compared to 2 in the control group.
   • Another study of adolescents and adults with leg ulcers (GBT440-042) reported 8 deaths among voxelotor users.
5. Global Impact: The recall affects all markets where Oxbryta is approved, and all active clinical trials and expanded access programs have been discontinued.
6. FDA Action: The FDA is conducting a safety review of postmarketing clinical trial data and real-world evidence.

Oxbryta Lawsuit Implications:

1. Potential Oxbryta Lawsuits: The defective drug attorneys at the Schmidt National Law Group are now beginning to pursue cases on behalf of individuals who may have suffered adverse effects or lost loved ones while using Oxbryta. We expect large cash settlements from the upcoming Oxbryta lawsuits from claims placed.
2. Accelerated Approval: Oxbryta received accelerated approval from the FDA, which may become a point of scrutiny in potential legal proceedings, the Schmidt National Law Group is investigating.
3. Manufacturer Liability: Questions arise regarding Pfizer’s responsibility in rushing the drug through the FDA approval process without adequate study.

The Schmidt National Law Group is concerned about this FDA recall and ready for litigation on behalf of affected patients. It also underscores the importance of monitoring drugs approved through accelerated pathways and the need for rigorous post-market surveillance.

As the situation develops stay informed about our ongoing Oxbryta investigations and any additional data released by Pfizer or the FDA regarding the safety profile of Oxbryta.

Sickle Cell Disease: A Brief Overview

Sickle Cell Disease (SCD) is a group of inherited red blood cell disorders affecting millions worldwide. Here’s what you need to know:

1. Cause: SCD is caused by a genetic mutation that affects hemoglobin, the protein in red blood cells that carries oxygen.
2. Characteristics:
   • Red blood cells become crescent or “sickle” shaped
   • These cells are rigid and sticky, causing blockages in small blood vessels
   • Sickle cells have a shorter lifespan, leading to anemia
3. Symptoms:
   • Pain crises (acute and chronic)
   • Fatigue
   • Increased risk of infections
   • Organ damage (heart, lungs, kidneys)
   • Stroke
4. Diagnosis:
   • Blood tests, including hemoglobin electrophoresis
   • Genetic testing
5. Treatment:
   • Pain management
   • Blood transfusions
   • Hydroxyurea (medication to reduce pain crises)
   • Bone marrow transplant (potential cure for some patients)
   • Gene therapy (emerging treatment)
6. Prevalence:
   • Most common in people of African, Middle Eastern, and South Asian descent
   • Affects approximately 100,000 Americans
7. Life Expectancy:
   • Has improved significantly with better treatments
   • Many patients now live into their 40s and beyond

Understanding SCD is crucial for dealing with cases related to this condition, especially in light of recent developments like the Oxbryta recall.

Take Action: Protect Your Rights

If you or a loved one has been affected by the Oxbryta recall or experienced complications from Sickle Cell Disease treatments, don’t face this challenge alone.

Our experienced team at the Schmidt National Law Group is here to help you understand your legal options and fight for the compensation you deserve.

Learn More About Your Rights in Defective Drug Cases

Don’t wait – contact us today for a free, confidential consultation. Let us be your voice in seeking justice and accountability in the wake of the Oxbryta recall.

Page: Oxbryta FDA Recall Lawsuit Claims & Settlements updated on 10/25/2024